These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 25487143)

  • 1. Antibodies targeting Clec9A promote strong humoral immunity without adjuvant in mice and non-human primates.
    Li J; Ahmet F; Sullivan LC; Brooks AG; Kent SJ; De Rose R; Salazar AM; Reis e Sousa C; Shortman K; Lahoud MH; Heath WR; Caminschi I
    Eur J Immunol; 2015 Mar; 45(3):854-64. PubMed ID: 25487143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparable T helper 1 (Th1) and CD8 T-cell immunity by targeting HIV gag p24 to CD8 dendritic cells within antibodies to Langerin, DEC205, and Clec9A.
    Idoyaga J; Lubkin A; Fiorese C; Lahoud MH; Caminschi I; Huang Y; Rodriguez A; Clausen BE; Park CG; Trumpfheller C; Steinman RM
    Proc Natl Acad Sci U S A; 2011 Feb; 108(6):2384-9. PubMed ID: 21262813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting Antigen to Clec9A Primes Follicular Th Cell Memory Responses Capable of Robust Recall.
    Kato Y; Zaid A; Davey GM; Mueller SN; Nutt SL; Zotos D; Tarlinton DM; Shortman K; Lahoud MH; Heath WR; Caminschi I
    J Immunol; 2015 Aug; 195(3):1006-14. PubMed ID: 26101322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficient and versatile manipulation of the peripheral CD4+ T-cell compartment by antigen targeting to DNGR-1/CLEC9A.
    Joffre OP; Sancho D; Zelenay S; Keller AM; Reis e Sousa C
    Eur J Immunol; 2010 May; 40(5):1255-65. PubMed ID: 20333625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Self-adjuvanting nanoemulsion targeting dendritic cell receptor Clec9A enables antigen-specific immunotherapy.
    Zeng B; Middelberg AP; Gemiarto A; MacDonald K; Baxter AG; Talekar M; Moi D; Tullett KM; Caminschi I; Lahoud MH; Mazzieri R; Dolcetti R; Thomas R
    J Clin Invest; 2018 May; 128(5):1971-1984. PubMed ID: 29485973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant-free peptide vaccine targeting Clec9a on dendritic cells can induce robust antitumor immune response through Syk/IL-21 axis.
    Gou S; Wang S; Liu W; Chen G; Zhang D; Du J; Yan Z; Wang H; Zhai W; Sui X; Wu Y; Qi Y; Gao Y
    Theranostics; 2021; 11(15):7308-7321. PubMed ID: 34158852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting antigen to mouse dendritic cells via Clec9A induces potent CD4 T cell responses biased toward a follicular helper phenotype.
    Lahoud MH; Ahmet F; Kitsoulis S; Wan SS; Vremec D; Lee CN; Phipson B; Shi W; Smyth GK; Lew AM; Kato Y; Mueller SN; Davey GM; Heath WR; Shortman K; Caminschi I
    J Immunol; 2011 Jul; 187(2):842-50. PubMed ID: 21677141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human CLEC9A antibodies deliver NY-ESO-1 antigen to CD141
    Masterman KA; Haigh OL; Tullett KM; Leal-Rojas IM; Walpole C; Pearson FE; Cebon J; Schmidt C; O'Brien L; Rosendahl N; Daraj G; Caminschi I; Gschweng EH; Hollis RP; Kohn DB; Lahoud MH; Radford KJ
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32737142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The STING activator c-di-AMP exerts superior adjuvant properties than the formulation poly(I:C)/CpG after subcutaneous vaccination with soluble protein antigen or DEC-205-mediated antigen targeting to dendritic cells.
    Volckmar J; Knop L; Stegemann-Koniszewski S; Schulze K; Ebensen T; Guzmán CA; Bruder D
    Vaccine; 2019 Aug; 37(35):4963-4974. PubMed ID: 31320219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody responses initiated by Clec9A-bearing dendritic cells in normal and Batf3(-/-) mice.
    Caminschi I; Vremec D; Ahmet F; Lahoud MH; Villadangos JA; Murphy KM; Heath WR; Shortman K
    Mol Immunol; 2012 Feb; 50(1-2):9-17. PubMed ID: 22209163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancing the immunogenicity of cancer vaccines by harnessing CLEC9A.
    Lahoud MH; Radford KJ
    Hum Vaccin Immunother; 2022 Dec; 18(1):1873056. PubMed ID: 33625943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody-mediated targeting of antigen to C-type lectin-like receptors Clec9A and Clec12A elicits different vaccination outcomes.
    Macri C; Dumont C; Panozza S; Lahoud MH; Caminschi I; Villadangos JA; Johnston AP; Mintern JD
    Mol Immunol; 2017 Jan; 81():143-150. PubMed ID: 27978488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205.
    Dhodapkar MV; Sznol M; Zhao B; Wang D; Carvajal RD; Keohan ML; Chuang E; Sanborn RE; Lutzky J; Powderly J; Kluger H; Tejwani S; Green J; Ramakrishna V; Crocker A; Vitale L; Yellin M; Davis T; Keler T
    Sci Transl Med; 2014 Apr; 6(232):232ra51. PubMed ID: 24739759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo targeting of antigens to human dendritic cells through DC-SIGN elicits stimulatory immune responses and inhibits tumor growth in grafted mouse models.
    Kretz-Rommel A; Qin F; Dakappagari N; Torensma R; Faas S; Wu D; Bowdish KS
    J Immunother; 2007 Oct; 30(7):715-26. PubMed ID: 17893564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced Humoral Responses Induced by Targeting of Antigen to Murine Dendritic Cells.
    Pugholm LH; Petersen LR; Søndergaard EK; Varming K; Agger R
    Scand J Immunol; 2015 Dec; 82(6):515-22. PubMed ID: 26346906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conjugation of an scFab domain to the oligomeric HIV envelope protein for use in immune targeting.
    King HAD; Gonelli CA; Tullett KM; Lahoud MH; Purcell DFJ; Drummer HE; Poumbourios P; Center RJ
    PLoS One; 2019; 14(8):e0220986. PubMed ID: 31430333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cross-presentation of dead-cell-associated antigens by DNGR-1
    Balam S; Kesselring R; Eggenhofer E; Blaimer S; Evert K; Evert M; Schlitt HJ; Geissler EK; van Blijswijk J; Lee S; Reis e Sousa C; Brunner SM; Fichtner-Feigl S
    Eur J Immunol; 2020 Dec; 50(12):2041-2054. PubMed ID: 32640051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimizing dendritic cell vaccine for immunotherapy in multiple myeloma: tumour lysates are more potent tumour antigens than idiotype protein to promote anti-tumour immunity.
    Hong S; Li H; Qian J; Yang J; Lu Y; Yi Q
    Clin Exp Immunol; 2012 Nov; 170(2):167-77. PubMed ID: 23039887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The C-type lectin receptor CLEC9A mediates antigen uptake and (cross-)presentation by human blood BDCA3+ myeloid dendritic cells.
    Schreibelt G; Klinkenberg LJ; Cruz LJ; Tacken PJ; Tel J; Kreutz M; Adema GJ; Brown GD; Figdor CG; de Vries IJ
    Blood; 2012 Mar; 119(10):2284-92. PubMed ID: 22234694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting CLEC9A delivers antigen to human CD141
    Tullett KM; Leal Rojas IM; Minoda Y; Tan PS; Zhang JG; Smith C; Khanna R; Shortman K; Caminschi I; Lahoud MH; Radford KJ
    JCI Insight; 2016 May; 1(7):e87102. PubMed ID: 27699265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.